Hyperphosphatemia Therapeutics Market Size, Share, Growth Analysis, By Product Type(Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2024-2031

Hyperphosphatemia Therapeutics Market Driver

• The increasing prevalence of chronic renal disease worldwide is one of the key factors propelling the market's growth. Due to its expanding global impact, it is predicted that by 2040, chronic kidney disease (CKD) would rank as the fifth most common cause of years lost globally. The overall number of individuals receiving dialysis has increased globally as a result of the rising prevalence of CKD. 785,883 Americans needed kidney transplants and dialysis in 2018, according to the National Kidney Foundation Inc. Of these people, dialysis was utilized to replace renal function in 554 338 cases. Nearly all dialysis-dependent renal failure patients experience hyperphosphatemia at some point in their lives. Additionally, according to the National Center for Biotechnology Information (NCBI), phosphate binders are used to treat 80–85% of dialysis patients who have hyperphosphatemia. Therefore, the market's growth during the forecast period will be greatly supported by the rising prevalence of chronic renal diseases.
• The number of new drugs being released in developing nations is expected to increase the demand for the hyperphosphatemia therapeutics market. For instance, in April 2021, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) published favorable results. Results of phase-Ill research on Velphoro (PA211) in China showed it could lower serum phosphorus in CKD patients over the age of dialysis. Such launch and pipeline products of hyperphosphatemia therapeutics are likely to aid the market growth in the upcoming years.

Hyperphosphatemia Therapeutics Market Restraint

• One of the main factors restraining the market's growth is poor treatment compliance among dialysis patients as a result of their heavy tablet load. For instance, a dialysis patient is typically expected to take 10 to 12 different types of drugs, according to a National Center for Biotechnology Information (NCBI) article. Nearly 80% of patients take four or more pills daily from phosphate binders, which can have negative side effects including gastrointestinal discomfort. Therefore, it is projected that these considerations will restrict CKD patients' use of phosphate binders, which will restrict the market's growth.